Company news

Insmed Incorporated news in 2026

Insmed Incorporated's news releases, calls and decks from 2026, newest first.

View company

Insmed to Present at November and December 2026 Investor Conferences

November 4, 2026

Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update

October 29, 2026

Insmed Appoints Two New Directors to Its Board

October 20, 2026

Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan

October 19, 2026

Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026

October 15, 2026

Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026

October 14, 2026

Insmed Announces CFO Transition

October 5, 2026

FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027

September 21, 2026

Insmed Expands Community Impact During Fifth Annual Global Day of Good

September 16, 2026

Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026

September 3, 2026

Insmed to Present at September 2026 Investor Conferences

August 26, 2026

BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

August 24, 2026

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

August 6, 2026

Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026

July 23, 2026

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

July 16, 2026

Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory

June 23, 2026

Insmed Reports Inducement Grants under NASDAQ Listing Rule 5635(4)

June 5, 2026

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

May 27, 2026

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

May 7, 2026

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

May 6, 2026

Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026

May 4, 2026

Insmed to Present at May 2026 Investor Conferences

April 30, 2026

Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026

April 23, 2026

Insmed Provides Clinical Update on Phase 2b CEDAR Study

April 7, 2026

Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease

March 22, 2026

Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update

February 19, 2026

Insmed To Present at March 2026 Investor Conferences

February 13, 2026

Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026

February 5, 2026

Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress

January 27, 2026

Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

January 8, 2026

Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference

January 1, 2026

Calls in 2026

Decks in 2026